GE
Genus plc
GENSF · OTC
$31.07 +0.00% (+$0.00)
Market Cap £1.52B
P/E Ratio 78.93x
Div. Yield 1.40%
ROE 3.78%
Bulios Fair Price
$28.58
8.0% downside
Current Price
$31.07
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GENSF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
41 /100
Fair P/E 78.93x
EV/EBITDA 18.58x
P/S 2.26x
Growth
19 /100
Declining EPS growth 26.12%
Rev. growth 4.27%
Book val. growth 6.32%
Profitability
48 /100
Moderate Gross margin 100.00%
Net margin 2.87%
Op. margin 6.30%
Quality
29 /100
Poor ROIC 5.41%
ROE 3.78%
ROA 2.15%
Debt
63 /100
Moderate Debt/Equity 0.56x
Current ratio 1.94x
Int. coverage 2.39x
Stability
64 /100
Moderate Beta 0.90x
Rev. volatility 10.23%
EPS volatility 94.42%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GENSF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jorgen Kokke
Employees
3,307
Headquarters
Basingstoke